 Cue Biopharma Inc NASDAQ: CUE has announced interim clinical data from its ongoing Phase 1a1b monotherapy study of CUE-101 as second-line treatment for patients with human papilloma virus-positive recurrentmetastatic head and neck squamous cell carcinoma HPV RM HNSCC. Interim analysis highlights include: Confirmed partial response PR in one patient and stable disease SD in five patients, providing early signs of potential single-agent activity of CUE-101. 